Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2023-04-25 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
关于2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company during the fiscal year 2022. It references regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange, and includes detailed financial figures on fundraising amounts, usage, balances, and compliance with relevant laws. It also includes opinions from the sponsor institution and an accounting firm regarding the proper use of the funds. The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds for the year 2022. This type of document corresponds to a Capital/Financing Update (CAP) as it focuses on fundraising activities, fund management, and usage rather than a full annual or interim report, audit report, or earnings release. The length and detail confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-04-25 Chinese
2022年度审计报告
Regulatory Filings
2023-04-25 Chinese
2022年年度股东大会通知公告
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2022 Annual General Meeting (AGM) of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items to be discussed, and procedural information for shareholders. It does not contain the actual annual report or financial statements but references other announcements where such reports are disclosed. The document is primarily an announcement about the AGM and related shareholder meeting logistics, not the report itself or voting results. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 4558 characters, which is consistent with a detailed AGM notice rather than a full report.
2023-04-25 Chinese
关于拟向银行申请授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's plan to apply for a bank credit facility (授信额度). It details the amount, purpose, board approval, and voting results. There is no financial statement or detailed financial data presented. The document is short (873 characters) and focuses on financing activities. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2023-04-25 Chinese
续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (信永中和会计师事务所) for the 2023 audit. It details the firm's background, integrity records, audit fee information, and the board's approval process. There are no financial statements or audit results included, only information about the audit firm and the procedural steps for reappointment. The document is relatively short (2516 characters) and serves as a formal announcement rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or financial statement. The confidence is high given the clear focus on audit firm reappointment and audit-related disclosures. FY 2023
2023-04-25 Chinese
信永中和会计师事务所关于云南生物谷药业股份有限公司2022年度财务报表出具非标审计报告的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation regarding a non-standard audit report issued for the 2022 financial statements of Yunnan Biological Valley Pharmaceutical Co., Ltd. It references the audit report issued on April 24, 2023, with a qualified opinion (保留意见). The content discusses audit findings, reasons for the qualified opinion, and relevant regulatory guidelines from the Chinese securities regulatory body. The document is clearly an audit report or audit-related information rather than a full annual report or other filing types. The length is short (1458 characters) but contains substantive audit content, not just an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.